Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
19788-1-AP targets ATRX-Specific in ELISA applications and shows reactivity with human samples.
| Tested Reactivity | human |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide 相同性解析による交差性が予測される生物種 |
| Full Name | alpha thalassemia/mental retardation syndrome X-linked (RAD54 homolog, S. cerevisiae) |
| Calculated molecular weight | 283 kDa |
| GenBank accession number | NM_000489 |
| Gene Symbol | ATRX |
| Gene ID (NCBI) | 546 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P46100 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
ATRX, also named as RAD54L and XH2, belongs to the SNF2/RAD54 helicase family. ATR could be a global transcriptional regulator. ATRX modifies gene expression by affecting chromatin. It may be involved in brain development and facial morphogenesis. Defects in ATRX are the cause of X-linked alpha-thalassemia/mental retardation syndrome (ATR-X) which is an X-linked disorder comprising severe psychomotor retardation, facial dysmorphism, urogenital abnormalities, and alpha-thalassemia. Defects in ATRX are the cause of mental retardation syndromic X-linked with hypotonic facies syndrome type 1 (MRXSHF1) which also called Carpenter-Waziri syndrome (CWS), Juberg-Marsidi syndrome (JMS), Smith-Fineman-Myers syndrome type 1 (SFM1). This antibody is specific to ATRX.